EQS-News: Numaferm and Zoetis Sign License Agreement to Collaborate on Developing and Producing Proteins and Peptides
Numaferm, a Germany-based biotech company, specialized in the production of pepteins, and Zoetis, the global leading animal health company, have signed a licensing agreement for the development and production of defined veterinary therapeutics.
- Numaferm, a Germany-based biotech company, specialized in the production of pepteins, and Zoetis, the global leading animal health company, have signed a licensing agreement for the development and production of defined veterinary therapeutics.
- Pepteins are an underdeveloped class of molecules located between PEPTides and protEINS (with a length of 30-300 amino acids).
- To date, peptein production via chemical synthesis or recombinant approaches is cumbersome, leading to time and resource-intensive development programs.
- The partnership collaboration with Zoetis is another milestone for Numaferm, demonstrating the value of our proprietary technologies for pharma projects and beyond.”